A study of the pharmacokinetics of moxifloxacin by the dynamics of its distribution in the blood plasma and saliva of healthy volunteers: a comparative analysis and possible extrapolation methods
-
Svetlana N. Kondratenko
and
Eugenia V. Shikh
Abstract
Objectives
The pharmacokinetics of moxifloxacin in plasma and saliva was investigated in this study.
Methods
The pharmacokinetics of two specialty drugs of moxifloxacin – reference (Ref) and test (Test) preparation – was studied in 18 healthy volunteers after a single oral dose of 400 mg.
Results
It was found that the concentration of moxifloxacin in saliva 3–24 h after taking the drugs was statistically significantly higher than that in plasma. A high correlation was observed between the concentration of moxifloxacin in plasma and saliva of volunteers after taking of Ref and Test. Some pharmacokinetic parameters, calculated by the concentration of moxifloxacin in saliva and plasma, are statistically different. A technique is proposed for extrapolating the concentration of moxifloxacin in plasma according to its concentration in saliva using the established linear relationship between the moxifloxacin in plasma and saliva of volunteers in time interval of 3–24 h after taking Ref. Based on the obtained extrapolated concentration of moxifloxacin, the pharmacokinetic parameters were calculated for two studied drugs and did not statistically differ from the parameters calculated according to the data in plasma.
Conclusions
The developed method of concentration extrapolation allows the use of saliva for pharmacokinetic studies of the tablet preparations of moxifloxacin.
Research funding: None declared.
Author contributions: All authors have accepted responsibility for the entire content of this manuscript and approved its submission.
Competing interests: Authors state no conflict of interest.
Informed consent: Informed consent was obtained from all individuals included in this study.
Ethical approval: The local Institutional Review Board deemed the study exempt from review.
References
1. Bondareva, IB, Budanov, SV, Bunyatyan, ND. Bioequivalence assessment of drugs. Moscow: Scientific Center Expertise of Medical Application; 2008.Search in Google Scholar
2. Karkishchenko, NN, Khoronko, VV, Sergeeva, SS, Karkishchenko, VN. Pharmacokinetics. Rostov-on-Don: Phenix; 2001.Search in Google Scholar
3. Miroshnichenko, II, Tyulyaev, II, Zuev, AP. Bioavailability of drugs. Moscow: Gramotey; 2003.Search in Google Scholar
4. van den Elsen, SHJ, Oostenbrink, LM, Heysell, SK, Hira, D, Touw, DJ, Akkerman, OW, et al. Systematic review of salivary versus blood concentrations of antituberculosis drugs and their potential for salivary therapeutic drug monitoring. Ther Drug Monit 2018;40:17–37. https://doi.org/10.1097/FTD.0000000000000462.Search in Google Scholar
5. Gallardo, E, Barroso, M, Queiroz, JA. Current technologies and considerations for drug bioanalysis in oral fluid. Bioanalysis 2009;1:637–67. https://doi.org/10.4155/bio.09.23.Search in Google Scholar
6. Sokolov, AV. Therapeutic drug monitoring. Qual Clin Pract 2009;1:71–3.Search in Google Scholar
7. Blue, RS, Bayuse, TM, Daniels, VR, Vorting, VE, Suresh, R, Mulcahy, RA, et al. Supplying a pharmacy for NASA exploration spaceflight: challenges and current understanding. Microgravity 2019;5:1–12. https://doi.org/10.1038/s41526-019-0075-2.Search in Google Scholar
8. Strachunsky, LS, Krechikov, VA. Moxifloxacin – a new generation of fluoroquinolone with a wide spectrum of activity. Clin Microbiol Antimicrob Chemother 2001;3:243–59.Search in Google Scholar
9. Burkhardt, O, Borner, K, Staß, H, Beyer, G, Allewelt, M, Nord, CE, et al. Single- and multiple-dose pharmacokinetics of oral moxifloxacin and clarithromycin, and concentrations in serum, saliva and faeces. Scand J Infect Dis 2002;34:898–903. https://doi.org/10.1080/0036554021000026963.Search in Google Scholar
10. Müller, M, Stass, H, Brunner, M, Moeller, JG, Lackner, E, Eichler, HG. Penetration of moxifloxacin into peripheral compartments in humans. Antimicrob Agents Chemother 1999;43:2345–9.10.1128/AAC.43.10.2345Search in Google Scholar PubMed PubMed Central
11. Troeltzsch, M, Pache, C, Probst, FA, Tröltzsch, M, Ehrenfeld, M, Otto, S. Antibiotic concentrations in saliva: a systematic review of the literature, with clinical implications for the treatment of sialadenitis. J Oral Maxillofac Surg 2014;72:67–75. https://doi.org/10.1016/j.joms.2013.06.214.Search in Google Scholar
12. Kumar, AK, Sudha, V, Srinivasan, R, Ramachandran, G. Simple and rapid liquid chromatography method for determination of moxifloxacin in saliva. J Chromatogr B Analyt Technol Biomed Life Sci 2011;879:3663–7. https://doi.org/10.1016/j.jchromb.2011.09.047.Search in Google Scholar
13. Stass, H, Dalhoff, A, Kubitza, D, Schühly, U. Pharmacokinetics, safety, and tolerability of ascending single doses of moxifloxacin, a new 8-methoxy quinolone, administered to healthy subjects. Antimicrob Agents Chemother 1998;42:2060–5. https://doi.org/10.1128/aac.42.8.2060.Search in Google Scholar
14. Kamali, F, Fry, JR, Bell, GD. Salivary secretion of paracetamol in man. J Pharm Pharmacol 1987;39:150–2. https://doi.org/10.1111/j.2042-7158.1987.tb06967.x.Search in Google Scholar
15. Kondratenko, SN, Starodubtsev, AK, Zolkina, IV, Belyakova, GA. Simulating the pharmacokinetics of tabletized ambroxol using the dynamics of drug distribution in saliva. Pharm Chem J 2009;43:77–80. https://doi.org/10.1007/s11094-009-0252-9.Search in Google Scholar
16. Posti, J. Saliva–plasma drug concentration ratios during absorption: theoretical considerations and pharmacokinetic implications. Pharm Acta Helv 1982;57:83–92.Search in Google Scholar
17. Kiang, TKL, Ensom, MHH. A qualitative review on the pharmacokinetics of antibiotics in saliva: implications on clinical pharmacokinetic monitoring in humans. Clin Pharmacokinet 2016;55:313–58. https://doi.org/10.1007/s40262-015-0321-z.Search in Google Scholar
18. Hold, K, Boer, D, Zuidema, J, Maes, R. Saliva as an analytical tool in toxicology. Int J Drug Test 1995;1:1–36.Search in Google Scholar
19. Nakashima, M, Uematsu, T, Kosuge, K, Kusajima, HI, Ooie, TS, Masuda, YU, et al. Single- and multiple-dose pharmacokinetics of AM-1155, a new 6-fluoro-8-methoxy quinolone, in humans. Antimicrob Agents Chemother 1995;39:2635–40. https://doi.org/10.1128/aac.39.12.2635.Search in Google Scholar
20. Koizumi, F, Ohnishi, A, Takemura, H, Okubo, S, Kagami, T, Tanaka, T. Effective monitoring of concentrations of ofloxacin in saliva of patients with chronic respiratory tract infections. Antimicrob Agents Chemother 1994;38:1140–3. https://doi.org/10.1128/aac.38.5.1140.Search in Google Scholar
© 2020 Walter de Gruyter GmbH, Berlin/Boston
Articles in the same Issue
- Editorial
- The need of the clinical implementation of pharmacogenetics in European health services for routine drug prescription. What’s next? An urgent clinical unmet need for patients
- Review
- Understanding COVID-19 in the light of epidemic disease described in Unani medicine
- Original Articles
- Pharmacogenetics of antipsychotics in adolescents with acute psychotic episode during first 14 days after admission: effectiveness and safety evaluation
- Using a pharmacogenetic clinical decision support system to improve psychopharmacotherapy dosing in patients with affective disorders
- A study of the pharmacokinetics of moxifloxacin by the dynamics of its distribution in the blood plasma and saliva of healthy volunteers: a comparative analysis and possible extrapolation methods
- Genotype-driven pharmacokinetic simulations of warfarin levels in Puerto Ricans
- Prognostic indicators in critically ill poisoned patients: development of a risk-prediction nomogram
- Related expression of TRKA and P75 receptors and the changing copy number of MYC-oncogenes determine the sensitivity of brain tumor cells to the treatment of the nerve growth factor in combination with cisplatin and temozolomide
- Genetic influence of DPYD*9A polymorphism on plasma levels of 5-fluorouracil and subsequent toxicity after oral administration of capecitabine in colorectal cancer patients of South Indian origin
- Methyl jasmonate delays the latency to anoxic convulsions by normalizing the brain levels of oxidative stress biomarkers and serum corticosterone contents in mice with repeated anoxic stress
- Diosmin attenuates schizophrenia-like behavior, oxidative stress, and acetylcholinesterase activity in mice
- Case Report
- NUDT15 polymorphism explains serious toxicity to azathioprine in Indian patients with chronic immune thrombocytopenia and autoimmune hemolytic anemia: a case series
Articles in the same Issue
- Editorial
- The need of the clinical implementation of pharmacogenetics in European health services for routine drug prescription. What’s next? An urgent clinical unmet need for patients
- Review
- Understanding COVID-19 in the light of epidemic disease described in Unani medicine
- Original Articles
- Pharmacogenetics of antipsychotics in adolescents with acute psychotic episode during first 14 days after admission: effectiveness and safety evaluation
- Using a pharmacogenetic clinical decision support system to improve psychopharmacotherapy dosing in patients with affective disorders
- A study of the pharmacokinetics of moxifloxacin by the dynamics of its distribution in the blood plasma and saliva of healthy volunteers: a comparative analysis and possible extrapolation methods
- Genotype-driven pharmacokinetic simulations of warfarin levels in Puerto Ricans
- Prognostic indicators in critically ill poisoned patients: development of a risk-prediction nomogram
- Related expression of TRKA and P75 receptors and the changing copy number of MYC-oncogenes determine the sensitivity of brain tumor cells to the treatment of the nerve growth factor in combination with cisplatin and temozolomide
- Genetic influence of DPYD*9A polymorphism on plasma levels of 5-fluorouracil and subsequent toxicity after oral administration of capecitabine in colorectal cancer patients of South Indian origin
- Methyl jasmonate delays the latency to anoxic convulsions by normalizing the brain levels of oxidative stress biomarkers and serum corticosterone contents in mice with repeated anoxic stress
- Diosmin attenuates schizophrenia-like behavior, oxidative stress, and acetylcholinesterase activity in mice
- Case Report
- NUDT15 polymorphism explains serious toxicity to azathioprine in Indian patients with chronic immune thrombocytopenia and autoimmune hemolytic anemia: a case series
